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As part of clinical diagnostics, saliva samples were obtained using commercially-available
Oragene collection kits by DNA Genotek and sent by regular mail directly from the families to the laboratory. DNA was extracted from the samples using the SPRI-TE nucleic acid extractor and the SPRI-TE gDNA extraction kit according to manufacturer's protocols.
Sequence-ready libraries for the MiSEQ DNA sequencer (Illumina) were prepared using the HaloPlex V2 library preparation kit (Agilent). Sensitivity and specificity for detection of known variants exceeded 99% and 99.99%, respectively, for the exonic sequence. Splice sites were evaluated as well. Variants suspected to be related to disease, including those in TRAP1,
were confirmed by Sanger sequencing performed on the original sample.
For this study, a significant sequence variant was defined as one that is highly predicted to alter protein structure or function (e.g. start, stop, frameshift and clear splicing variants corresponding to ACMG categories 4 or 5), or very-highly conserved missense variants. The latter of which we defined as complete evolutionary conservation through all vertebrates (to spotted gar, a primitive fish; the lamprey sequence is absent from the database) per the UCSC Genome Browser. Poorly aligned sequences were discounted, and a single species with a different amino acid sequence was allowed to account for potential sequence error in the database. This was done with the understanding that very-highly conserved variants may or may not be relevant, yet lesser-conserved missense variants are not as likely to have biological relevance. Based on being relatively-common and per our prior clinical suspicion, p.Ile253Val was analyzed separately. In addition, the potential clinical relevance of sequence variants was determined based on the modeled protein's structure. The crystal structure of wild-type zebrafish TRAP1 protein was published [8] . Using this structure as the main template, the structure for human TRAP1 was modeled computationally [9] . All variants identified in our patients were mapped to the in silico model to predict pathogenesis, and
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6 those missense variants identified as likely pathogenic (hereafter termed as "possible missense disruptors" or "disruptors") were analyzed. Another experimental group consisted of patients with a nonsense mutation (stop codon) in the TRAP1 gene. Control groups included published sequence databases representing the general population (1000Genomes, ESP, ExAC), and our patients in which no variants were identified in the TRAP1 gene.
Limited clinical information was provided with the samples in order to facilitate clinical sequence interpretations, and only this pre-existing information was used for the present retrospective study. Individuals were excluded if no clinical information was available or the available information was inadequate. Adequate clinical information included an informative clinical summary, a comprehensive evaluation, or a completed checklist provided by a treating physician. The above-described limited data set, containing no personal identifiers, was used for the present study. Families were not contacted in regards to the current study.
Our primary, preexisting hypothesis, based upon our review of the available medical records in the first five cases, was that p.Ile253Val and other highly-conserved variants within the ATPase domain of the TRAP1 protein are associated with chronic pain, fatigue and GI dysmotility, which will be subsequently referred to in this paper as the "functional triad".
Additionally, these are the only functional conditions common enough among our patient cohort to allow for statistical evaluation by the present methodology. A set of keywords was used to search the laboratory reports for these three functional disease categories. A manual search verified the inclusion, and identified strings such as "without migraine" or "family history of migraine" for exclusion. Pain was defined as the inclusion of the word "pain" or any of the common manifestations such as "headache", "migraine", "myalgia", etc. We defined fatigue to include exercise intolerance and muscle weakness, because we did not believe
that the available clinical information reliably distinguished among these entities. We defined "GI dysmotility" to be the presence of any symptomatic diagnosis suggestive of abnormal gut transit speed including gastrointestinal reflux disease, gastroparesis, delayed gastric emptying, constipation, diarrhea, irritable bowel and the term "GI dysmotility". Since many of the initial patients had an autistic spectrum disorder, relevant search terms were queried in a secondary, exploratory analysis. No other clinical conditions were queried. All subjects are unrelated to our knowledge, and family members were excluded.
Statistics are given as odds ratio and 95% confidence interval (OR, 95%CI) with the calculated P value per http://www.medcalc.org/calc/odds_ratio.php. The amino acid change in either of two "salt bridge" variants abolishes their interaction, which we judged as crucial for protein function (see Discussion), and thus both variants were analyzed together.
Determination of the predominate racial, ethnic and geographic backgrounds of our patients were performed by principal component analysis using the smartpca program incorporated into the EIGENSOFT program along with variants that were part of the initial call set from the 1000 Genomes (1000g) Project Phase3 analysis (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/) [10, 11] . This release contains 79 million variants and is based on data from 2,535 individuals comprising 26 different populations around the world. This set of 79 million variants is reduced to a set of at least 43,455 SNPs that overlaps our panel. Each of our patient samples is genotyped for these panel-overlap SNPs using the Genome Analysis Toolkit UnifiedGenotyper and the patient sample is put through the smartpca workflow along with genomes for the 1000g samples.
After smartpca completes, geometric distance scores are calculated between the patient sample and all 2,535 1000g individuals using the first 10 principal components (where n = The distances are ranked by which are closest to the patient samples and the most commonly occurring ethnicity in the top ten is retained as the ethnicity that most closely resembles the patient sample.
RESULTS
Among the 930 patients referred for sequencing in which adequate clinical information was provided, a very-highly conserved variant in the TRAP1 gene was identified in 73 patients (Table 1) . Ten of the 23 very-highly conserved missense variants were predicted to be "disruptors" to protein function; there were no predicted disruptors among the lesser-conserved amino acids.
Functional disease categories were compared between patients with different types of variants in the TRAP1 gene and in patients in which no TRAP1 variants were identified (Table 2 ). In addition to the statistics listed in that table, very-highly conserved variants within 11/10/9/8 "Common mutation" p.Glu267Lys
No 1 2 Terms defined in the Methods section; salt bridges are covered in the Discussion. 3 One case has both p.Glu192Lys and p.Ile253Val, phase unknown 4 One case has both p.Glu267Lys and (p.Tyr444Asn + p.Arg692His), phase unknown and Arg469His, as well as the moderately-conserved polymorphism Arg692His, demonstrate no association with the three functional categories (data not shown). 6 Phase was determined in five of the seven cases, all in cis 1 The functional categories are defined in the Methods section. 2 All three functional categories are present in the patient (per provided records). 3 One patient with the triad has both Glu192Lys and Ile253Val. 4 Missense variants predicted based on structure to affect protein function, as described in Methods, and excluding the relatively-common p.Ile253Val variant.
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11 5 Missense variants predicted based on structure NOT to affect protein function. 6 The lid covering the ATP-binding pocket; see Discussion 7 Presence of a stop codon, which can be assumed to result in no protein. 
14 TRAP1, are highly-conserved molecular chaperones that, in one of their functions inhibit cell death caused by reactive oxygen species (ROS) [12] .
Figure 1. Computer model of a TRAP1 protein dimer
The ATPase domain of TRAP1 hydrolyses the energy-rich bond of ATP, which like in other HSP90 proteins [13] , is involved in processing proteins in an energy-requiring manner. In our data, three TRAP1 variants were identified in at least two patients with the functional triad: (one patient has two of the variants). The "common mutation" p.Ile253Val alone, as well as the two "salt bridge mutations" collectively, are very-highly associated (P < 0.0005) with the functional triad of chronic pain, fatigue and GI dysmotility. The odds ratios are quite high with point estimates of 7.5 and 18 ( Table 2 ). The data is just as striking when the proportion of patients with these variants in our study with the functional triad is compared to the proportion of patients with these variants in the general population, giving odds ratio point estimates of 10 and 17.
The major limitation of this study is the dearth of clinical information. In order to maintain the confidentiality of the subjects and the non-human-subject designation of the study, we were confined to a limited data set extracted from retrospective intakes and sequences. In most cases, the clinical information available to us was fairly limited, and the ascertainment of functional symptomatology is certainly incomplete. However, there is no reason to suggest that there is any systemic bias in assigning phenotype, which was done blind to genotype.
Symptom ascertainment should be equally incomplete in all patients, and low sensitivity would create false negatives that would favor the null hypothesis. Indeed, when the five patients with p.Ile253Val referred by the first author (symptoms determined from the
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16 comprehensive clinic note) were compared to the other 11 patients (symptoms determined from any one of the means listed in the Methods section), it appears that our methodology underestimates patients with functional symptomatology, and the actual odds ratios may be higher than those presented herein.
Another disadvantage of the dearth of clinical information is that the extent of the phenotype associated with the three TRAP1 variants cannot be presently elucidated. Based on the few patients for whom we have more detailed clinical information, it appears that the TRAP1-related phenotype does extend beyond the triad to include additional functional symptomatology such as chronic dizziness and episodic palpitations/tachycardia. Several of the patients are disabled by their disease, including persistent ongoing pain, severe fatigue meeting the Fukuda definition of chronic fatigue syndrome, intestinal failure on total parental nutrition and/or persistent dizziness that prevents walking at school. However, the TRAP1 variants are compatible with a broad range of severity, as among the few cases in which full clinical evaluations were provided, relatives carrying the variant (determined by Sanger sequencing) demonstrate a wide range of symptomatology, from the lack of all functional symptoms to substantial disability resulting from the full triad. Additionally, there is not enough data to assess any cognitive effects of these variants, except to say that many patients appear to have normal to near-normal intelligence. It is presently unclear if the observed statistically-significant association of non-253 conserved ATPase variants in TRAP1 with autistic spectrum disorders is real, although the presence of that spectrum in 5/7 patients with salt bridge mutations does suggest that further investigation is indicated.
Recently a single patient with a heterozygous p.Ile253Val variant in TRAP1 was described as having multiple congenital anomalies consistent with VACTERL association (MIM #192350).
However, this patient and the other four VACTERL patients described in that article all had one or two C-terminal variants in TRAP1 [14] . In addition, one child with a homozygous Cterminal variant in TRAP1 was reported to have the severe mitochondrial disorder of Leigh syndrome [5] . The structure of TRAP1 implies a very complicated dimerizing region in the Cterminal domain, and variants in this domain generally decrease ATPase activity while variants in the ATPase domain increase ATPase activity [8] . While primarily a mitochondrial matrix protein, TRAP1 has also been identified in nonmitochondrial locations including pancreatic zymogen granules, insulin secretory granules, cardiac sarcomeres, and the nuclei of heart and pancreatic cells, suggesting broader functions [15] . The role of TRAP1 as a protector against oxidative stress was one of its earliest recognized functions. Different groups have observed that overexpressing TRAP1 resulted in a reduction of oxidative damage and apoptosis in response to agents known to be toxic to mitochondria (deferoxamine and cisplatin, respectively), suggesting that TRAP1 plays a role in protecting mitochondria by reducing reactive oxygen species (ROS) levels [16, 17] . Inversely, one group observed that silencing TRAP1 through RNA interference increases ROS accumulation [18] .
Since the connection between oxidative stress and functional disease has been supported in several studies, it is not surprising that TRAP1-related disease can lead to functional symptomatology. Oxidative damage, as measured by lipid peroxidation, is associated with clinical symptoms in patients with fibromyalgia [19] . Headaches, in particular in these patients, appear to be related to oxidative stress [20, 21] . Furthermore, antioxidants have been found to be valuable in treating functional disease, such as chronic fatigue [22, 23] , migraine [24] and gastrointestinal dysmotility [25] . Early anecdotal clinical reports from our patient population suggest substantial improvement in symptoms, at least with regards to pain and fatigue, in those patients followed by the first author. Clinical studies are planned.
Defective chaperone function in the TRAP1 protein, due to mutations in the ATPase domain, might result in erroneous protein processing (e.g. mis-folding), and such a gain-of-function would likely result in the dominant inheritance (variant on one allele is related to disease despite a normal gene copy on the other allele) that is observed in our cases. Dominantlyinherited chaperonopathies have been described, including early-onset torsion (DYT1) [26, 27] and myofibrillar myopathy (CRYAB) [28, 29] . Although numbers are small, the high degree of the functional triad among the three cases with nonsense variants in TRAP1 (Table 2) suggest that the mechanism for p.Ile253Val-related functional symptomatology may instead be a loss-of-function/haploinsufficiency. Thus, the mechanism is unclear, and in vitro functional studies are planned.
The p.Ile253Val variant in the TRAP1 gene is not rare as it is present in nearly one of 100 peoples from Europe. Collectively, p.Ile253Val, p.Glu192Lys or p.Arg128His is found in about 1-2% of peoples from Europe. Functional disease, including fatigue, pain and gut dysmotility, is relatively common, and therefore the presence of functional disease-predisposing variants being present in as many as 1-2% of some populations is not surprising. The presumed
19 gross model herein is that these are common variants that predispose towards the development of some common conditions, in a multifactorial and polygenic manner. 
CONCLUSION
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